Development and Validation of a Mass Spectrometry–Based Assay for the Molecular Diagnosis of Mucin-1 Kidney Disease  by Blumenstiel, Brendan et al.
The Journal of Molecular Diagnostics, Vol. 18, No. 4, July 2016jmd.amjpathol.orgDevelopment and Validation of a Mass
SpectrometryeBased Assay for the Molecular
Diagnosis of Mucin-1 Kidney Disease
Brendan Blumenstiel,* Matthew DeFelice,* Ozge Birsoy,*y Anthony J. Bleyer,z Stanislav Kmoch,x Todd A. Carter,*
Andreas Gnirke,* Kendrah Kidd,z Heidi L. Rehm,*y Lucienne Ronco,* Eric S. Lander,* Stacey Gabriel,* and Niall J. Lennon*From the Broad Institute of MIT and Harvard,* Cambridge, Massachusetts; the Partners Healthcare Laboratory for Molecular Medicine,y Cambridge,
Massachusetts; the Nephrology Section,z Wake Forest Baptist Medical Center, Winston-Salem, North Carolina; and the Institute for Inherited Metabolic
Disorders,x Charles University in Prague, Prague, Czech RepublicAccepted for publicationC
T
hMarch 9, 2016.
Address correspondence
to Brendan Blumenstiel, B.A.,
Broad Institute of MIT and
Harvard, 320 Charles St.,
Cambridge, MA 02141. E-mail:
brendan@broadinstitute.org.opyright ª 2016 American Society for Inve
his is an open access article under the CC B
ttp://dx.doi.org/10.1016/j.jmoldx.2016.03.003Mucin-1 kidney disease, previously described as medullary cystic kidney disease type 1 (MCKD1, OMIM
174000), is an autosomal dominant tubulointerstitial kidney disease recently shown to be caused by a
single-base insertion within the variable number tandem repeat region of the MUC1 gene. Because of
variable age of disease onset and often subtle signs and symptoms, clinical diagnosis of mucin-1 kidney
disease and differentiation from other forms of hereditary kidney disease have been difﬁcult. The causal
insertion resides in a variable number tandem repeat region with high GC content, which has made
detection by standard next-generation sequencing impossible to date. The inherently difﬁcult nature of
this mutation required an alternative method for routine detection and clinical diagnosis of the disease.
We therefore developed and validated a mass spectrometryebased probe extension assay with a series
of internal controls to detect the insertion event using 24 previously characterized positive samples
from patients with mucin-1 kidney disease and 24 control samples known to be wild type for the
variant. Validation results indicate an accurate and reliable test for clinically establishing the molecular
diagnosis of mucin-1 kidney disease with 100% sensitivity and speciﬁcity across 275 tests called.
(J Mol Diagn 2016, 18: 566e571; http://dx.doi.org/10.1016/j.jmoldx.2016.03.003)Supported by the Slim Initiative for Genomic Medicine, a project funded
by the Carlos Slim Foundation of Mexico.
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application covering the method described in this article.Previously described asmedullary cystic kidney disease type 1
(MCKD1), mucin-1 kidney disease (MKD) is a genetic sub-
classiﬁcation of a larger family of autosomal dominant tubu-
lointerstitial kidney diseases.1 Although mucin-1 is expressed
in many tissues in the body, the only clinical consequence of
MKD is slowly progressive deterioration of kidney function,
leading to the need for dialysis or kidney transplantation.1,2
Furthermore, the pathological changes that occur in the
kidney are nonspeciﬁc, meaning that pathological studies of
kidney biopsy specimens from these patients will also not
reveal a speciﬁc diagnosis. Because there are no other signs of
this condition, a genetic assay is the only way to diagnose
MKD and differentiate it from many other causes of kidney
disease. MKD is considered a rare disease, but its low preva-
lence may be in part due to current difﬁculties in diagnosis.
Once MKD is diagnosed within a family, it still remains
difﬁcult to predict disease risk in individual familystigative Pathology and the Association for M
Y-NC-ND license (http://creativecommons.orgmembers. The loss of kidney function is variable, with some
patients starting dialysis in the third decade of life, whereas
other family members may have relatively preserved kidney
function into their 70s. The only clinical method available to
detect disease risk in a family member is to test the serum
creatinine level. However, this test is not sensitive for early
disease stages because kidney function can be reduced
before an increase in serum creatinine level.3e5 It also is not
speciﬁc because many individuals in the population have
mild elevations in their serum creatinine from other condi-
tions. Thus, clinical diagnosis of this condition often is notolecular Pathology. Published by Elsevier Inc.
/licenses/by-nc-nd/4.0).
Diagnosis of Mucin-1 Kidney Diseasepossible, leading to uncertainty regarding disease status in
many family members. In addition, as kidney function
worsens, many patients with MKD will require kidney
transplantation. Siblings are often the best candidates for
kidney donation, but in the past many siblings have not been
allowed to donate because of the inability to rule out disease
risk. In some cases siblings have donated and later been
found to have MKD. Thus, the development of a genetic
assay will allow family members to learn whether they are at
risk for MKD and also will allow for the transplantation of
many affected individuals through the ability to rule out
MKD in potential family donors.6e8
MKD is caused by a single-base insertion within a large
variable number tandem repeat (VNTR) unit (60 bp) of the
MUC1 gene, which encodes the transmembrane proteinMucin
1. The single-base cytosine insertion event resides in repeat
region with high GC content (>80%) and expands a 7-bp
cytosine homopolymer (7C) to an 8-bp homopolymer (8C).
The addition of the cytosine residue causes a frameshift,
resulting in a premature stop codon and a truncated protein
lacking the downstream self-cleavage module expressed in the
wild-type version.9
Three factors make detection of the variant by next-
generation sequencing and traditional genotyping methods
extremely difﬁcult. First, the insertion event is believed to
occur in a different yet speciﬁc repeat unit, depending on
family. Coupled with the fact that the repeat number can
vary from 20 to 125 for an individual, directly targeting
the variant 60-bp unit with anchored primers outside the
VNTR is unlikely.10 Because of the highly skewed allelic
ratio of mutant to wild-type copies of the repeat, detecting
a 0.8% to 5% alternate signal within a high (95% to
99.2%) wild-type background makes standard genotyping
assays unreliable for a clinical setting. Second, the
high GC nature of the repeat domain leads to underrep-
resentation in both targeted exome and whole-genome
sequencing. Third, because the insertion expands a 7C
homopolymer to 8Cs (þC ), even if the region is sufﬁ-
ciently covered with next-generation sequencing reads, the
low allelic ratio variant would likely be interpreted as a
sequencing error.11,12
In early efforts to validate the þC single-base insertion
as the causal variant responsible for MKD, a genotyping
method that would enrich for and detect the rare mutation
within a strong wild-type background was needed. Fortu-
itously, it was discovered that the þC insertion destroyed a
restriction site cleaved by endonuclease MwoI. Digestion of
the wild-type 60-bp repeat domain enabled preenrichment
of the intact þC domain for downstream interrogation. To
detect the þC insertion, genomic DNA (gDNA) was
digested with MwoI, and the remaining intact repeat units
were ampliﬁed using tailed PCR primers ﬂanking the
variant site. A second MwoI digestion further digested any
remaining ampliﬁed wild-type fragments. Interrogation of
the þC base was performed by probe extension and
detection by matrix-assisted laser desorption/ionizationThe Journal of Molecular Diagnostics - jmd.amjpathol.orgtime-of-ﬂight (MALDI-TOF) mass spectrometry using the
Sequenom MassArray system (Sequenom, San Diego, CA).
During initial assay development, six MKD-affected
families, consisting of 62 symptomatic and 79 unaffected
individuals, were genotyped along with 500 control in-
dividuals from the Japanese, Chinese, Yoruban, and Tuscan
HapMap 3 populations. Results revealed that the þC
insertion segregated perfectly with the disease risk haplo-
type within the affected families and was completely absent
in all 500 controls.
Our aim was to further develop and validate this robust
assay to be used as a clinical molecular diagnostic test for
MKD. To establish the analytical validity of the optimized
assay, we retrospectively tested 24 samples with known
clinical family history of MKD, which were found to be
positive for the þC insertion within a research setting, and
24 negative Hap Map control samples.
Materials and Methods
Patients, Samples, and DNA Extraction
We obtained puriﬁed genomic DNA extracted from blood
for 24 individuals enrolled in an ongoing MKD research
project in collaboration with Anthony J. Bleyer, M.D., and
Wake Forest University Baptist Medical Center. All 24
individuals consented for research and had a family history
of kidney disease. Previous testing under the research
protocol revealed that all individuals harbored the MKD-
associated þC insertion. Samples were deidentiﬁed and
assigned a unique alphanumeric code for sample tracking.
Genomic DNA derived from 24 HapMap cell lines were
used as negative controls for the validation (Coriell Cell
Repository, Camden, NJ).
Multiplex Primer Design and Enrichment
Fifty nanograms of genomic DNA was digested to
completion using 10 units of restriction endonuclease MwoI
(New England Biolabs, Beverly, MA), which selectively
cleaves the wild-type 7C (GCCCCCCCAGC) sequence re-
peats while leaving intact mutant 8C fragments containing
the þC insertion (GCCCCCCCCAGC). After a 2 SPRI
cleanup using Ampure XP beads (Beckman Coulter, Brea,
CA), tailed primers nested within the 60-bp repeat unit were
then used to PCR amplify the remaining intact VNTR
fragments, thus enriching for duplication-containing frag-
ments over wild-type background. As a control for gDNA
template addition and enzymatic steps, a nonpolymorphic
region of the housekeeping gene GAPDH was multiplexed
in the same PCR reaction. PCR was performed in a 25-mL
reaction volume using 0.8 units of Hot Start Plus Taq
Polymerase (Qiagen, Hilden, Germany), supplied reaction
buffer at 1, 1 mmol/L MgCl2, 0.76 mmol/L dNTP,
0.2 mmol/L of each primer, MKD forward (50-CTGG-
GAATCGCACCAGCGTGTGGCCCCGGGCTCCACC-30),567
Figure 1 Matrix-assisted laser desorption/ioni-
zation time-of-ﬂight mass spectrometry spectra
readout of a wild-type negative sample (A) and þC
positive sample (B). Unextended probe products
are indicated by asterisks. Successful restriction
digestion is indicated by a strong peak at 4889.21
Da and low-intensity peak at 5162.4 Da (MwoI
control). Reaction performance is indicated by the
GAPDH control extension product at 5557.63 Da. þC
insertion event indicated by a peak at 5904.83 Da
(shaded area).
Blumenstiel et alMKD reverse (50-CGTGGATGAGGAGCCGCAGTGTCC-
GGGGCCGAGGTGACA-30), GAPDH forward (50-CG-
CGGTAAAACGACGGCCAGAAGGCTGTGGGCAAG-
GTC-30), GAPDH reverse (50-GGCCCGACAGGAAA-
CACGTATGACCCTGCTTCACCACCTTCTTG-30). PCR
was performed using the following cycling conditions: initial
denaturation of 5 minutes at 95C followed by 45 cycles of
(30 seconds at 94C, 30 seconds at 62C, and 1 minute at
72C) and a ﬁnal extension of 10 minutes per 72C. Then
samples were stored at 4C until further processing. PCR
reactions were then cleaned again using 2 SPRI. Once
amplicons were eluted, a second digestion with MwoI was
used to further digest any ampliﬁed wild-type repeat units,
further enriching for mutant þC product.
MwoI Digestion Control
To control for successfulMwoI digestion, a nonhuman 132-bp
amplicon was spiked in to the second digestion reaction. This
amplicon contained a singleMwoI restriction site, whichwhen
cut produces two fragments 101 and 31 bp in length. Suc-
cessful digestion was assayed via probe extension multiplexed
with the MKD and GAPDH assays in the following steps.
Probe Extension and Analyte Detection
Oligonucleotide probes were speciﬁcally designed to inter-
rogate the þC insertion and the GAPDH and MwoI diges-
tion controls. Probe extension was performed in a 10-mL
reaction volume using 1.28 units of Thermosequenase
(Sequenom); 0.7 PCR buffer (Qiagen); 0.22 iPlex
Buffer Plus (Sequenom); 0.6 mmol/L MgCl2; 0.19 mL SAP
Buffer (Sequenom); 0.22 mmol/L each deoxyadenosine
triphosphate, 2’,3’-dideoxycytidine-5’-triphosphate, and
2’,3’-dideoxyguanosine-5’-triphosphate; 0.6 mmol/L each
oligo probe, MKD probe (50-CGGGCTCCACCGCCCCC-
CC-30), GAPDH probe (50-CCTGAGCTGAACGGGAA-30),568and MwoI probe (50-AATCGTGATCTAGCA-30). Probe
extension was performed using the following cycling condi-
tions: 2 minutes at 94C followed by 75 cycles of (5 seconds
at 94C, 5 seconds at 52C, and 5 seconds at 72C) and a ﬁnal
extension of 7 minutes at 72C. Then samples were stored
at 4C until further processing. Reactions were then desalted
using 6 mg of Clean Resin cationic exchange resin
(Sequenom).
Analyte pools for each sample were then co-crystalized
with organic matrix (3-hydroxypicolinic acid) on a 384-spot
silica chip using a pin tool and detected by MALDI-TOF
mass spectrometry using the Sequenom Mass Array plat-
form. Spectral data were generated, and analyte intensity
and signal to noise values (SNR) were recorded.
Analysis and Genotype Calling
Genotype calling is performed by analyzing the resulting
extension products for the three multiplexed probes
(Figure 1). Thresholds were set based on empirical obser-
vation of signal during research and development runs.
GAPDH Control
To control for template addition, PCR ampliﬁcation, SPRI
clean-up, and probe extension reactions, a 151-bp region of
the GAPDH gene (chr12:6,646,867-6,647,017) is PCR
ampliﬁed and interrogated with a 17-bp extension probe. An
SNR >15 for an extension product at 5244.43 Da represents
a passing reaction.
Mwo-Negative Control
To control for successful MwoI digestion, a nonhuman,
synthetic, 132-bp amplicon, which contains a single MwoI
restriction site, is spiked into the second digestion reaction.
Digestion is interrogated with a 15-bp extension probe
positioned a single base upstream of the cut site. A suc-
cessful restriction digestion is indicated by a singlejmd.amjpathol.org - The Journal of Molecular Diagnostics
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Figure 2 Flowchart of mucin-1 kidney disease
(MKD) calling. Signal to noise ratios (SNRs) for
four potential peaks are used to determine the
test result. Conclusive calls of wild-type (nega-
tive) or þC (positive) are only reported when both
the GAPDH and MwoI () controls pass the set
thresholds. Samples with low but detectable
signal for the MKD extension product (SNR, 1.5 to
15) are called inconclusive.
Diagnosis of Mucin-1 Kidney Diseasedeoxyadenosine triphosphate termination product at 4889.21
Da with a SNR>10 and an SNR<10 for a two-base addition
2’,3’-dideoxycytidine-5’-triphosphate termination product at
5162.40 Da.
MKD Assay
For the detection of the þC insertion, a 20-bp probe is
positioned just upstream of the insertion site. If the þC
insertion event is present, the probe will be terminated with
a 2’,3’-dideoxyguanosine-5’-triphosphate, resulting in an
extension analyte at 5904.83 Da.
There are four possible call outcomes for this assay, and
they are determined for each sample by assessing the SNR
for the four possible extension analytes (Figure 2). SNR
thresholds for each call type have been established by values
from previously performed replicate experiments and were
reassessed and conﬁrmed in this validation.
Assay Fail
GAPDH extension analyte SNR at 5557.62 Da is <15,
MwoI control extension analyte SNR at 4889.21 Da is <10,
and analyte SNR at 5162.40 Da is >10.
þC (Positive)
MKD extension analyte SNR at 5904.83 Da is 15 with
passing MwoI and GAPDH controls.
Wild Type (Negative)
MKD extension analyte SNR at 5904.83 Da is <1.5 with
passing MwoI and GAPDH controls.
Inconclusive
MKD extension analyte SNR at 5904.83 Da is <15 and
1.5 with passing MwoI and GAPDH controls.The Journal of Molecular Diagnostics - jmd.amjpathol.orgResults
The 48 validation samples were analyzed by two indepen-
dent technologists (B.B., M.D.), both performing the testing
in duplicate for each sample in each run. One technologist
repeated the experiment a second time for a total of six
replicate runs of the sample set. Using the calling thresholds
described in MKD Assay, all six replicate runs were called
(Figure 3). Call rate, precision, accuracy, and analytical
sensitivity and speciﬁcity were determined.
Of 288 total samples detected, three failed either the
GAPDH or Mwo (negative) control and were called assay
fail for a rate of 1%. Of the 285 passing samples, 10
samples were called inconclusive for a rate of 3.5%. Of
the 275 samples that generated conclusive calls of either
þC (positive) or wild type (negative), no false-negative or
false-positive calls were made against the known refer-
ence, indicating analytical sensitivity and speciﬁcity of
the test to be 100%. All conclusive calls made were
concordant with their known reference for an accuracy of
100%. Although conclusive call rates varied from 83% to
100% across the six replicate runs, performed by two
technologists (B.B., M.D.) across three different days, no
discrepant conclusive calls were made, and assay preci-
sion was maintained with 100% repeatability and repro-
ducibility (Table 1).
In addition to the standard 50-ng DNA input, we also
tested assay performance across a range of DNA input
amounts. The 48 validation samples were tested in a single
run with both 20-ng and 100-ng total DNA input. No
discordant calls were made against sample reference for
100% accuracy. Analytical sensitivity and speciﬁcity were569
Figure 3 A: The distribution of peak signal to noise ratios (SNRs) for the mucin-1 kidney diseaseþC analyte at 5904.83 Da was observed for all 384 validation
reactions. Results binned by known sample reference. Eleven of 384 reactions generated a SNR between 1.5 and 15 (shaded area) and were called inconclusive.
B: Distribution of GAPDH control extension analyte SNR at 5557.63 Da for 384 assays performed during validation. Three of 384 wells failed because the signal was
below the set SNR threshold of 15 (dotted line). C: Successful MwoI restriction digestion is determined by assessing the two potential extension products of a
probe interrogating the restriction site of a synthetic amplicon spike in. One of 384 assays failed the MwoI control with a signal below the SNR threshold of 10
(dotted line) at mass 4889.21 Da. Both peak values are plotted for 384 assay wells run in the validation. Data presented as distributions with outlier box plots.
Blumenstiel et al100%. Conclusive call rates for 20-ng and 100-ng inputs
were 98% and 100%, respectively, demonstrating that the
test performance is consistent across a ﬁvefold range of
input material.Discussion
The inherent nature of this causal mutation for MKD makes
it extremely difﬁcult to detect using standard diagnostic
detection methods. The high GC content of approximately
85%, the variable length of the VNTR, and a mutation
involving a single-base expansion of a cytosine homopol-
ymer make standard sequencing technologies unreliable for
rapid and accurate diagnosis in the clinic. The restriction
enzyme MwoI cuts wild-type 7C copies of the 60-bp repeat
unit while leaving intact the mutated 8C units, allowing
us to develop a detection method around the enzymatic
enrichment of mutant signal over wild-type background. By
relying on separation of analytes by molecular mass using
MALDI-TOF mass spectrometry, we are able to clearly
distinguish signal intensity derived from both mutant and
wild-type products with very high speciﬁcity. Although the
presence of the þC insertions is quite easy to resolve, with a
typically strong analyte peak at the expected size in theTable 1 Reproducibility of Assay Across Eight Replicates of the 48 Sa
Validation set Technologist
Inconclusive
(%)
Assay
fail (%)
True-posi
rate (%)
Plate 1, replicate 1 A 2 0 100
Plate 1, replicate 2 A 0 0 100
Plate 2, replicate 1 A 0 2 100
Plate 2, replicate 2 A 0 2 100
Plate 3, replicate 1 B 15 2 100
Plate 3, replicate 2 B 4 0 100
Mean 3.5 1 100
Plate 4, 20 ng A 2 0 100
Plate 4, 100 ng A 0 0 100
Although one replicate run shows a higher inconclusive rate of approximately
570readout spectra, calling a wild-type or negative patient relies
on interpreting the lack of a signal. This could lead to a
higher likelihood of false-negative calls, resulting from
technical or process errors, such as no gDNA template
addition, thermocycler failure, or poor elution during reac-
tion cleanup. Incorporation of a multiplexed assay targeting
the GAPDH housekeeping gene allows us to control for all
steps in the process and is built into the result calling logic.
By automating the assay using robotic liquid handlers, we
can simultaneously process up to 89 patient samples along
with seven control wells in standard 96-well format. From
DNA receipt to result generation, we can typically generate
batch results in approximately ﬁve days, allowing us to
quickly report the molecular diagnosis of a patient back to
the ordering physician.
The test that was validated in this study only looks for a
þC insertion; however, other insertions or deletions within
the VNTR could potentially result in the same truncated
form of the Mucin 1 protein and thus manifest as MKD.
Interestingly, no other mutations in MUC1 have thus far
been reported as causal for MKD, suggesting that if alter-
native mutations exist, they are rare. In addition, the position
of the mutation within the VNTR (early or late unit of the
entire repeat region) could possibly contribute to the vari-
able age of onset seen in affected patients. Unfortunately,mple Validation Set
tive True negative
rate (%)
Analytical
sensitivity (%)
Analytical
speciﬁcity (%)
Accuracy
(%)
100 100 100 100
100 100 100 100
100 100 100 100
100 100 100 100
100 100 100 100
100 100 100 100
100 100 100 100
100 100 100 100
100 100 100 100
15%, analytical sensitivity, speciﬁcity, and accuracy all remain at 100%.
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Diagnosis of Mucin-1 Kidney Diseasealthough the test presented here detects the presence of the
causal variant in one single copy of the VNTR sequence, it
does not identify the speciﬁc repeat unit from which it
originates. Ultimately, long read sequencing that can accu-
rately read through the entire 20- to 125-copy VNTR region
will be required to positively identify the position of the
mutation in most patients.
The development of a successful genetic assay, for a
condition in which a clinical diagnosis often cannot be
made, will lead to immediate improvements in the care of
patients with MKD. Although there is no speciﬁc therapy
available for MKD, there are a number of tangible beneﬁts.
First, patients can obtain a genetic diagnosis without the risk
of a kidney biopsy that would often fail to provide a diag-
nosis. Second, siblings of affected individuals can be tested
and appropriately cleared for kidney transplantation. Third,
the progression of kidney disease in this disorder, and fac-
tors affecting it, can be better studied. Fourth, the condition
can be studied in individuals who are minimally affected.
Fifth, patients can be identiﬁed for interventional trials.
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